UNIVERSITI PUTRA MALAYSIA

ANTIFUNGAL PEPTIDE MODELING, FOLDING AND MIMETIC DESIGN

SHOEIB MORADI
FBSB 2009 30
ANTIFUNGAL PEPTIDE MODELING, FOLDING AND MIMETIC DESIGN

By

SHOEIB MORADI

Thesis submitted to the School of Graduate Studies, Universiti Putra Malaysia, in Fulfilment of the Requirements for the Degree of Master of Science

October 2009
ANTIFUNGAL PEPTIDE MODELING, FOLDING AND MIMETIC DESIGN

By

SHOEIB MORADI

October 2009

Chairman:  Nor Aripin Shamaan, PhD
Faculty:  Biotechnology and Biomolecular Sciences

The antifungal peptides represent diverse structures for drug design. Unfortunately, they provide inferior drug candidates because of their low oral bioavailability, potential immunogenicity, poor \textit{in vivo} metabolic stability and high molecular weight. Recent efforts have focused on the creation of non-natural peptide mimetics. Their artificial backbone makes most peptidomimetics resistant to degradative enzymes, thus, increasing the stability of peptidomimetic drugs in the body. In the present study, four antifungal peptidomimetics structures named \( C_1 \) to \( C_4 \) were designed based on the antifungal decapeptide crystallized structure of Pep-1 using bioinformatics tools. Structures \( C_1 \) and \( C_2 \) belong to the N-terminal part of Pep-1 and \( C_3 \) and \( C_4 \) belong to the C-terminal amino acid sequence part of Pep-1. Minimum inhibitory concentrations (MIC) of these structures were estimated against \textit{Aspergillus niger} N402, \textit{Candida albicans} ATCC 10231, and \textit{Saccharomyces cerevisiae} PTCC 5052. Structures \( C_2 \) and \( C_1 \) showed more potent antifungal activities against these fungal strains compared to \( C_3 \).
and C₄, respectively. This demonstrated that the N-terminal part is more potent for antifungal activity and indicated that the N-terminal part of antifungal peptides is more active and important for antifungal activity than the C-terminal. Structure C₂ was demonstrated to be more active against these microorganisms and could be used as a potential target for future antifungal peptidomimetics studies. Important factors/descriptors of 63 antifungal peptides have been studied using Artificial Neural Network (ANN). The most important factors determined were amino acid number 1 (S1), Log P, and their α-helix contents. This is the first study on the structure of C₁ to C₄ peptidomimetics on *Aspergillus niger* N402, *Candida albicans* ATCC 10231, and *Saccharomyces cerevisiae* PTCC 5052.
Abstrak ini dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk Ijazah Master Sains

**PERMODELAN, PENGLIPATAN DAN REKABENTUK PEPTIDA MIMETIK ANTIKULAT**

Oleh

**SHOEIB MORADI**

Oktobor 2009

Pengerusi: Nor Aripin Shamaan, PhD

Fakulti: Bioteknologi dan Sains Biomolekul

dan C₁ menunjukkan aktiviti antikulat yang kuat terhadap ketiga-tiga species kulat yang
dikaji berbanding C₃ dan C₄. Ini membuktikan bahawa bahagian terminal-N
mengandungi aktiviti antikulat yang lebih kuat berbanding terminal-C dan bahagian
terminal-N peptida antikulat adalah lebih aktif dan penting dari terminal-C. Struktur C₂
mempamerkan aktiviti antikulat yang tinggi terhadap kulat yang dikaji dan
berkemungkinan menjadi sasaran untuk kajian masa hadapan bagi peptida mimetik
antikulat. Kajian ke atas 63 peptida antikulat telah dilakukan dengan menggunakan
jaringan artifisial neural (Artificial Neural Network, ANN). Faktor paling penting yang
ditentukan ialah asid amino pertama dalam jujukan (S1), Log P dan isi kandungan α-
heliks. Kajian ini merupakan kajian pertama ke atas struktur C₁ hingga C₄ peptida
mimetik Aspergillus niger N402, Candida albicans ATCC 10231, dan Saccharomyces
cerevisiae PTCC 5052.
ACKNOWLEDGEMENT

Hymn the praises be to thy Lord, who ever ready to show mercy, and refuge us from evil.

I specially thank Prof. Nor Aripin Shamaan who trusted and supported me during these 2 academic years.

I would like to thank Dr. Sorosh Sardari for serving not only as my supervisor, but also in my life that changed my insight about my living manner and taught me how to see the world. He provides continuous guidance and support throughout during these two years graduate work.

I also thank my other committee member Dr. Mohd. Puad Abdullah.

I am grateful to my all lecturers during these two years of study in Malaysia especially Dr. Foo Hooi Ling for her help and recommendations.

Moreover, I should really thank my parents for their financial support in addition to being my sponsor during my stay in Malaysia and for their patience. I am grateful to them and the rest of family members my sisters and my little brother, and encouragement during difficult periods in my study and my life.

Finally I would like to thank all my friends in Pasteur Institute of Iran especially Mr. Saeed Soltani for his help during my study, and also thank Mohammad, Sina, Mahdi, Morteza, Amir.
APPROVAL
This thesis submitted to the Senate of University Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Master of Science. The members of the Supervisory Committee are as follows:

**Internal Supervisor Committee Members:**

**Nor Aripin Shamaan, Ph.D**  
Professor  
Faculty of Biotechnology and Biomolecular Science  
University Putra Malaysia  
(Chairman)

**Mohd. Puad Abdullah, Ph.D**  
Associate Professor  
Faculty of Biotechnology and Biomolecular Science  
University Putra Malaysia  
(Member)

**External Supervisor Committee Member:**

**Soroush Sardari, Ph.D**  
Associate Professor  
Eastern Mediterranean Health Genomics and Biotechnology Network  
Pasteur Institute of Iran  
(Member)

---

**HASANAH MOHD GHAZALI, PhD**  
Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia  
Date:
DECLARATION

I hereby declare that this thesis is based on my original work, except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously or concurrently submitted for any other degree at UPM or any other institution.

______________________________
Shoeib Moradi
Date: 14th October 2009
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>II</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSTRAK</td>
<td>IV</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENT</td>
<td>VI</td>
</tr>
<tr>
<td>APPROVAL</td>
<td>VII</td>
</tr>
<tr>
<td>DECLARATION</td>
<td>IX</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>XII</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>XIII</td>
</tr>
<tr>
<td>LIST OF ABBREVIATIONS</td>
<td>XV</td>
</tr>
</tbody>
</table>

## CHAPTER

### 1 INTRODUCTION

1.1. Background

1

### 2 LITERATURE REVIEW

2.1. Antimicrobial Peptides

2.1.1. Introduction

4

2.1.2. Classification of Antimicrobial Peptides

13

2.1.3. Mechanisms of action

18

2.1.4. Structure Activity Relationship (SAR)

22

2.1.5. Defensins

27

2.2. Peptidomimetics

28

2.2.1. Definition

28

2.2.2. Classification of Peptidomimetics

28

2.2.3. Antimicrobial Peptidomimetics

30

### 3 MATERIALS AND METHODS

3.1. Data collection

35

3.2. Neural Network

45

3.3. Sequences Alignments

49

3.4. Mimetic Design

50

3.5. Antifungal Screening

52
# LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>Antifungal peptides, their sources and typical target organism</td>
<td>15</td>
</tr>
<tr>
<td>2.1</td>
<td>Antifungal peptides, their sources and typical target organism. (Cont.)</td>
<td>16</td>
</tr>
<tr>
<td>2.1</td>
<td>Antifungal peptides, their source and typical target organism. (Cont.)</td>
<td>17</td>
</tr>
<tr>
<td>3.1</td>
<td>Some of AFPs descriptors using different softwares, online servers, and databases.</td>
<td>36</td>
</tr>
<tr>
<td>3.1</td>
<td>Some of AFPs descriptors using different softwares, online servers, and databases. (Cont.)</td>
<td>37</td>
</tr>
<tr>
<td>3.1</td>
<td>Some of AFPs descriptors using different softwares, online servers, and databases. (Cont.)</td>
<td>38</td>
</tr>
<tr>
<td>3.1</td>
<td>Some of AFPs descriptors using different softwares, online servers, and databases. (Cont.)</td>
<td>39</td>
</tr>
<tr>
<td>3.2</td>
<td>Antifungal peptides, their Amino acids sequences, molecular weight and their sources.</td>
<td>46</td>
</tr>
<tr>
<td>3.2</td>
<td>Antifungal peptides, their Amino acids sequences, molecular weight and their sources. (Cont)</td>
<td>47</td>
</tr>
<tr>
<td>3.2</td>
<td>Antifungal peptides, their Amino acids sequences, molecular weight and their sources. (Cont.)</td>
<td>48</td>
</tr>
<tr>
<td>3.3</td>
<td>Peptidomimetics compounds formula and their Molecular weight.</td>
<td>51</td>
</tr>
<tr>
<td>4.1</td>
<td>Antifungal effect of compounds against <em>Aspergillus Niger</em>, <em>Candida albicans</em>, and <em>Saccharomyces cerevisiae</em>, as obtained by the broth dilution method.</td>
<td>62</td>
</tr>
</tbody>
</table>
### LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1.</td>
<td>Antimicrobial peptides are made by many cells in skin and have multiple functions.</td>
<td>8</td>
</tr>
<tr>
<td>2.2.</td>
<td>The multifunctional properties and functions of AMPs.</td>
<td>9</td>
</tr>
<tr>
<td>2.3.</td>
<td>Multifunctional properties of lactoferrin.</td>
<td>10</td>
</tr>
<tr>
<td>2.4.</td>
<td>The membrane target of antimicrobial peptides of multicellular organisms and the basis of specificity.</td>
<td>11</td>
</tr>
<tr>
<td>2.5.</td>
<td>Scheme illustrating the proposed role of cationic peptides in innate immunity.</td>
<td>12</td>
</tr>
<tr>
<td>2.6.</td>
<td>Molecular models of the different structural classes of cationic peptides.</td>
<td>13</td>
</tr>
<tr>
<td>2.7.</td>
<td>Sketch of different models describing the functional mechanisms and underlying structure of antimicrobial peptides interacting with lipid bilayers.</td>
<td>21</td>
</tr>
<tr>
<td>2.8.</td>
<td>A schematic view of magainin pores in a lipid bilayer crystallized into a regular hexagonal lattice.</td>
<td>22</td>
</tr>
<tr>
<td>2.9.</td>
<td>Structure of alpha and beta alanine.</td>
<td>31</td>
</tr>
<tr>
<td>2.10.</td>
<td>$\alpha$, $\beta^2$ and $\beta^3$ general structures.</td>
<td>32</td>
</tr>
<tr>
<td>4.1.</td>
<td>Most relative importance factors which determined by ANN.</td>
<td>55</td>
</tr>
<tr>
<td>4.2.</td>
<td>The correlation coefficients between the experimental and the predicted IC$_{50}$ value pertaining to all the AFPs.</td>
<td>55</td>
</tr>
<tr>
<td>4.3.</td>
<td>Most relative sensitivity factors which determined by ANN.</td>
<td>56</td>
</tr>
<tr>
<td>4.4.</td>
<td>Final Sequences alignment among AFPs that led to final pattern.</td>
<td>56</td>
</tr>
<tr>
<td>4.5.</td>
<td>Final pattern.</td>
<td>57</td>
</tr>
<tr>
<td>4.6.</td>
<td>Result of blast search.</td>
<td>57</td>
</tr>
<tr>
<td>4.7.</td>
<td>Sequence details of 1JKZ.</td>
<td>58</td>
</tr>
<tr>
<td>4.8.</td>
<td>Peptidomimetic structures that designed by SuperMimic Program.</td>
<td>60</td>
</tr>
<tr>
<td>4.9.</td>
<td>Final compounds for antifungal screening which named C$_1$, C$_2$, C$_3$ and C$_4$.</td>
<td>61</td>
</tr>
</tbody>
</table>
4.10. Compounds antifungal activity results against 
*Candida albicans* and *Aspergillus niger*.  

63

4.11. Antifungal activity results of compounds against 
*Saccharomyces cerevisiae*.  

64
LIST OF ABBREVIATIONS

/ Per
°C Degree Celsius
µg Microgram
µH/µH max Relative-amphipathicity
µM Micro Molar
3D Three-Dimentional
ACE Angiotensin-converting enzyme
AFPs Antifungal peptides
AMPs Antimicrobial peptides
ANN Artificial Neural Networks
BLAST Basic local alignment search tool
Cα Alpha-carbon
CAMD Computer-Aided Molecular Design
Cβ Beta-carbon
Cys Cysteine
CFU Colony forming unit
Cont. Continued
D Dalton
DMSO Dimethyl sulfoxide
DPM Double prediction Method
Drs Drosomycin
ECM Extracellular matrix
h Hour
HBD Human beta-defensin
HIV Human immunodeficiency virus

XV
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC&lt;sub&gt;50&lt;/sub&gt;</td>
<td>Inhibitory concentration</td>
</tr>
<tr>
<td>IgA</td>
<td>Immunoglobulin A</td>
</tr>
<tr>
<td>ITR</td>
<td>Itraconazole</td>
</tr>
<tr>
<td>LAP</td>
<td>Lingual antimicrobial peptide</td>
</tr>
<tr>
<td>LPS</td>
<td>Lipopolysaccharide</td>
</tr>
<tr>
<td>LTA</td>
<td>Lipoteichoic acid</td>
</tr>
<tr>
<td>MIC</td>
<td>Minimum inhibitory concentration</td>
</tr>
<tr>
<td>ml</td>
<td>Milliliter</td>
</tr>
<tr>
<td>NMR</td>
<td>Nuclear magnetic resonance</td>
</tr>
<tr>
<td>NP</td>
<td>Neutrophils</td>
</tr>
<tr>
<td>pI</td>
<td>Isoelectric point</td>
</tr>
<tr>
<td>PDB</td>
<td>Protein Data Bank</td>
</tr>
<tr>
<td>PMN</td>
<td>Polymorphonuclear</td>
</tr>
<tr>
<td>QSAR</td>
<td>Quantitative structure activity</td>
</tr>
<tr>
<td>RMSD</td>
<td>Root mean square deviation</td>
</tr>
<tr>
<td>SAR</td>
<td>Structure-activity relationships</td>
</tr>
<tr>
<td>SE</td>
<td>Syringomycin-E</td>
</tr>
<tr>
<td>SMB</td>
<td>Sabouraud maltose broth</td>
</tr>
<tr>
<td>TF</td>
<td>Tissue factor</td>
</tr>
<tr>
<td>TL</td>
<td>Thaumatin-like</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
</tr>
</tbody>
</table>
CHAPTER I

INTRODUCTION

1.1. Background and Objectives

In the past 10 years, the frequency of fungal disease has increased noticeably (Hong et al., 2001). Multiple-drug resistances have appeared leading to the discovery of novel drugs to combat these through diverse mechanisms of actions. Antimicrobial peptides (AMPs) are an evolutionarily conserved component of the innate immune response and are found among all classes of life. These peptides are potent, broad spectrum antibiotics which demonstrate potential as novel therapeutic agents. These AMPs are found from diverse sources ranging from primary eukaryotes to mammalian having typically fewer than 60 amino acids long, containing cationic amino acid residues and an amphiphilic structure bound to the membrane (α-helical and/or β-sheet). Many of these peptides are unstructured in free solution, and fold into their final configuration upon partitioning into biological membranes.

The ability to associate with membranes is a definitive feature of antimicrobial peptides (Dhople, et al. 2006) although membrane permeabilisation is not necessary. These peptides have a variety of antimicrobial activities ranging from membrane permeabilization to action on a range of cytoplasmic targets. It appears as though many peptides initially isolated as and termed “antimicrobial peptides” have been shown to have more significant alternative functions in vivo (e.g. hepcidin) (Brogden, 2005). These peptides are excellent candidates for development as novel therapeutic agents and complements to conventional antibiotic therapy because in
contrast to conventional antibiotics they do not appear to induce antibiotic resistance while they generally have a broad range of activity, are bacteriocidal as opposed to bacteriostatic and require a short contact time to induce killing.

A number of naturally occurring peptides and their derivatives have been developed as novel anti-infective therapies for conditions as diverse as oral mucositis, lung infections associated with cancer (Amsterdam, 1996), and topical skin infections. Pexiganan has been shown to be useful to treat infection related diabetic foot ulcer. The application of peptides as drugs is difficult due to their poor oral and tissue absorption, quick proteolytic cleavage and weak half-life or stability. Since the majority of proteins and small peptides are simply proteolyzed, quickly excreted and poorly bioavailable, a lot attempt has been exhausted to discover ways to replace portions of peptides with non-peptide structures, termed peptidomimetics which are to mimic peptide in the expectation of achieving more bioavailable units. Their artificial backbone is resistant to proteases, as well. Peptidomimetics are one set of probes utilized in the shift pathway of tiny molecule drug design.

In recent times considerable advancement has been made in use of Computer-Aided Molecular Design (CAMD) of novel molecules. These techniques normally rely on two steps: the first being forward modelling, through which Quantitative Structure Activity Relationship (QSAR) procedure is accomplished by application of non-linear modelling procedures such as Artificial Neural Networks (ANN). The second step is model inversion/optimization which utilizes optimization of algorithms in exploitation of the first stage result in discovery of molecules with enhanced activity. Several factors have an effect on the activity of antifungal peptides like sequence, size, charge, degree of structure formation, cationicity, hydrophobicity,
amphipathicity, hydrophobic moment and pH. ANN possibly will aid us to calculate approximately the significance of these structural parameters in bioactivity of AFPs and finally the most possible model of AFPs’ mechanism of action.

In the current study, important factors/descriptors in antifungal peptides have been studied and 4 antifungal peptidomimetics structures were designed based on antifungal peptide structures, using different design methods by means of bioinformatics as a computational studies, rather than synthesize first and test antimicrobial peptidomimetics strategy.

Objectives:

Two objectives have been followed in this study which are:

1. *In silico* study of potential features/descriptors in antifungal peptides molecules.

2. Design of antifungal peptidomimetics structure using cheminformatics/bioinformatics tools.
CHAPTER II

LITERATURE REVIEW

2.1. Antimicrobial Peptides

2.1.1. Introduction

Multi-drug resistance against generally used antibiotics has turn into an essential community health trouble all over the world (Lohner, 2001; Novak et al., 1999). Although the occurrence of resistance is not new, being first proposed by Sir Alexander Fleming with regard to penicillin more than 60 years in the past, it has become of greater than ever concern as more and more antibiotics are caused to be ineffective. Furthermore, resistance at this moment also includes effective antibacterial agents which are used as a last resort, e.g. methicillin and vancomycin. Around 30% of hospital strains of Enterococci are vancomycin resistant and almost half of the infections caused by Staphylococcus aureus are methicillin resistant (Straus and Hancock, 2006). In the last two decades, the occurrence of human fungal infections has increased significantly; in parallel with the broad extend of untreatable infectious diseases connected with antibiotic resistant bacteria (Jang et al., 2006). Of the thousands of recognized fungal species, just about 175 are pathogenic and generate mycotic infections in humans and animals (Duggineni et al., 2007). As of 2003, over 57% of Staphylococcus aureus infections in US intensive care units were resistant to multiple antibiotics (National Nosocomial Infections Surveillance (NNIS) System Report). Fungal infections are significant reasons of morbidity and mortality in hospitalized patients: candidiasis is the fourth most general blood culture isolates in US hospitals (Pfaller et al., 1998), pulmonary aspergillosis is the leading cause of
death in bone marrow transplant recipients (Panutti et al., 1992), and *Pneumocystis carinii* pneumonia is the leading cause of death in AIDS patients in North America and Europe fungal diseases have been converted into an emergent hazard, principally in immunocompromised patients, for which few or no effective drugs are currently obtainable (Lupetti et al., 2002). The incidence of fungal infections that have been seen in the increasing populations of immunocompromised hosts, counting individuals infected with HIV, aging, organ transplantation, and patients with cancer, has increased dramatically in the last few decades (Pears & Patterson, 2002). The AIDS epidemic, enhanced life-sustaining therapy, and aggressive anticancer therapy have supplied to the increase in the quantity of severely immunocompromised patients (Helmerhorst et al., 1999). This has led to a raise in mucosal and systemic fungal infections, and the simultaneous increased usage of antifungal agents for prophylaxis is most likely the main reason of the improvement of antifungal drug resistance (White et al., 2001).

The yeast fungus, *Cryptococcus neoformans*, has been recognized as the fourth most regular from of life-threatening infection in AIDS patients (White et al., 2001). Potentially fatal infections with *Candida albicans* and other species of *Candida* are in addition identified (Kovacs et al., 1985). Additionally, antifungal drugs frequently make use of various unfavourable effects and are irregularly dose-limiting. In such conditions, a novel scheme is for the control of fungal infections. Aspergillosis and candidiasis, which are typically caused by *Aspergillus fumigatus* and *Candida albicans*, respectively, are the most repeated of fungal infections (Clark & Hajjeh, 2002). In agriculture, enormous economic losses are caused by the infestation of crop plants with fungal pathogens (Szappanos et al., 2006). The infection with plant pathogens such as *Fusarium* spp. not only causes severe yield losses, crop damage
and decreases in quality of grain, but far more considerably, may also pollute the grain with mycotoxins, which are dangerous to animal and human wellbeing (Edwards, 2004). Human fungal pathogens are exceedingly different group of fungal species, and *Candida albicans*, *Aspergillus fumigatus*, and *Cryptococcus neoformans* are the three most significant pathogens causing severe systemic infections among the immunocompromised population (Groll & Walsh, 2001).

At this time, efficient drug therapy to treat fungal infections is very limited and dominated by the azole class of antifungals, which selectively inhibit lanosterol demethylase activity, a late step in ergosterol biosynthesis (Geogopapadakou & Walsh, 1996; Green et al., 1999; Sheehan et al., 1999). Although the azole antifungals have admirable safety profiles and are orally bioavailable, they are not fungicidal and therefore have need of long therapeutic treatment. Subsequently, their extensive use has led to an increasing incidence of drug resistance (Sussman et al., 2004).

Scientists have consequently concentrated their efforts on the design and advancement of new classes of antimicrobial agents that acquire novel modes of action that could conquer recognized mechanisms of antibiotic resistance. An attractive approach consists of probing for naturally occurring antibiotic molecules and both the plant and animal kingdom are rich sources. For that reason, in the search for an alternative form of treatment for fungal infections, the last decade has seen a spreading out in innovative approaches, like therapeutic antibodies and peptide molecules (Hancock, 1999; Kumar et al., 2005). Accordingly, there is a greater concern in the pharmacological application of antimicrobial peptides to treat infection, and the development of a new class of anti-infective agents.
Antimicrobial peptides are capable candidates for novel therapeutic agents because of their low toxicity against mammalian cells, do not easily select resistant mutants (Duggineni et al., 2007), and are therapeutic agents against microbes and their unique biological mechanisms of perturbing the membrane of the pathogen (Hong et al., 2001). They are a new resource of potential new antibiotic drugs because they were proposed to interact directly with lipid bilayers, resulting in pore-forming or alteration of the cell membrane permeability and eventually cell death (Sitaram & Nagaraj, 1999; Shai, 1999). On the other hand, some of these agents have got to clinical trials, whereas others are undergoing detailed preclinical testing (Hancock 1999), the search for such antifungal peptides continues, especially in selecting an effective candidate for the development of a new type of antibiotic. Antimicrobial peptides (AMPs) make natural antibiotics the basic element of a novel generation of drugs for the treatment of bacterial and fungal infections (Delucca, 2000; Welling et al., 2000; Selitrennikoff, 2001). Figure 2.1 shows that these peptides are made by many cells in skin and have multiple functions. Peptides are expressed in layers providing antimicrobial barrier at surface when secreted by eccrine glands and can be made by keratinocytes when activated. Resident and recruited bone marrow-derived cells such as mast cells and neutrophils also express high levels of antimicrobial peptides. Functions attributed to these peptides extend well beyond activity as simple antibiotic. Select molecules will influence cytokine release and synthesis of components of the extracellular matrix (ECM), and are chemotactic and angiogenic (Izadpanah & Gallo, 2005).
AMPs, effectors molecules of the innate immune system, present a first line of defense against invading pathogens, promise to be a solution to this problem (Ganz, 1999; Lohner & Epand, 1997). Antimicrobial peptides are small molecules that serve in the vertebrate and invertebrate world for both offensive and defensive purposes as part of the immune defense system (Shai, 1999). Figure 2.2 describes some functions of AMPs.